Recent changes to supplies of angiotensin-converting enzyme (ACE) inhibitors in Aotearoa New Zealand include:
- cilazapril with hydrochlorothiazide (Inhibace Plus) – discontinued 2020
- quinapril with hydrochlorothiazide (Accuretic) – withdrawn October 2022
- cilazapril – to be delisted in 2024
The withdrawal of Inhibace Plus and Accuretic has meant patients have had to be changed to alternative agents. In addition, Pharmac has been encouraging prescribers to move away from the use of cilazapril to minimise the impact on patients and on prescriber workflows when cilazapril becomes unavailable in 2024.
To help with these changes, new ACE inhibitor options are being listed on the pharmaceutical schedule including a higher dose perindopril tablet (8mg available 1 October 2022) and ramipril capsules (available 1 December 2022). These add to the group of existing funded agents that affect the renin-angiotensin system:
- ACE inhibitors – enalapril, lisinopril, quinapril
- angiotensin receptor blockers (ARBs) – candesartan, losartan, losartan with hydrochlorothiazide, and sacubitril with valsartan (for heart failure patients who meet special authority criteria).